Opinion|Videos|August 1, 2024

Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

Author(s)Elias Jabbour, MD, Evandro D. Bezerra, MD, Lori Muffly, MD

The panel explores the potential impact of obecabtagene autoleucel on the treatment landscape and decision-making process for acute lymphoblastic leukemia, contingent upon its FDA approval.

Episodes in this series

5 KOLs are featured in this series.

EP. 1 Overview of CAR T-cell Therapies in R/R B-cell ALL

5 KOLs are featured in this series.

EP. 2 CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

5 KOLs are featured in this series.

EP. 3 Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

5 KOLs are featured in this series.

EP. 4 Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

5 KOLs are featured in this series.

EP. 5 Overview of Available Treatment Options in R/R B-cell ALL

5 KOLs are featured in this series.

EP. 6 Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

5 KOLs are featured in this series.

EP. 7 Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

5 KOLs are featured in this series.

EP. 8 Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

5 KOLs are featured in this series.

EP. 9 Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

5 KOLs are featured in this series.

EP. 10 Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

5 KOLs are featured in this series.

EP. 11 Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

5 KOLs are featured in this series.

EP. 12 Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

5 KOLs are featured in this series.

EP. 13 Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

5 KOLs are featured in this series.

EP. 14 Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

5 KOLs are featured in this series.

EP. 15 Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

5 KOLs are featured in this series.

EP. 16 Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

5 KOLs are featured in this series.

EP. 17 Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

5 KOLs are featured in this series.

EP. 18 Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

5 KOLs are featured in this series.

EP. 19 Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

5 KOLs are featured in this series.

EP. 20 Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

How do you foresee obe-cel impacting treatment decisions or landscape, if FDA approved??

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Breast Cancer

October 21st, 2026

Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings

Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.

MIBC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

October 21st, 2026

Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC

The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.

Image by Ashling Wahner & MJH Life Sciences Using AI

October 21st, 2026

Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC

Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.

Mayo Clinic | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

October 21st, 2026

Body Composition Changes on CT Scans May Help Identify Pancreatic Cancer Risk

Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.

CLL/SLL | Image Credit: © Nicat - stock.adobe.com

October 21st, 2026

Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL

Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.

Andrea Cercek, MD

October 21st, 2026

FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer

Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.

Fadi Haddad, MD

October 20th, 2026

Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML

Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.

RCC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

October 20th, 2026

Casdatifan Demonstrates Activity in Advanced Clear Cell RCC

Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.

Trending on OncLive

FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer

Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML

Casdatifan Demonstrates Activity in Advanced Clear Cell RCC

HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management

Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL